Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY13.63 CNY
Change Today +0.02 / 0.15%
Volume 7.4M
As of 3:00 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

hainan shuangcheng pharmac-a (002693) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/25/15 - CNY14.45
52 Week Low
04/28/14 - CNY5.73
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HAINAN SHUANGCHENG PHARMAC-A (002693)

Related News

No related news articles were found.

hainan shuangcheng pharmac-a (002693) Related Businessweek News

No Related Businessweek News Found

hainan shuangcheng pharmac-a (002693) Details

Hainan Shuangcheng Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of chemically synthesized peptide drugs and active pharmaceutical ingredients. It provides Thymalfasin for injection, which is used in the treatment of chronic hepatitis B, as well as used as a vaccine for patients with immune system functions suppressed; and Levocarnitine for injection to treat carnitine deficiency induced complications. The company also offers Clindamycin Hydrochloride for injection for amygdalitis, suppurative otitis media, and nasosinusitis; acute bronchitis, acute episode of chronic bronchitis, pneumonia, lung abscess, and bronchiectasia concurrent infection; skin and soft tissue infections; urinary system infection, acute urethritis, acute pyelonephritis, and prostatitis; and osteomyelitis, septicemia, peritonitis, and oral infection. In addition, it provides Thymopentin for injection to treat chronic hepatitis B; various primary or secondary T cell immunodeficiency diseases, such as children innate immunodeficiency disease; autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, etc.; various diseases with impaired cell immunity functions; and supplementary treatment of rumor diseases. Further, the company offers Famotidine for injection for patients with peptic ulcer hemorrhage; and intercurrent acute gastric mucosal lesion under stress condition, and gastrointestinal bleeding that is caused by nonsteroidal anti-inflammatory drugs. Additionally, it provides Somatostatin for injection for treating acute haemorrhage from oesophageal varices; acute haemorrhage from gastric or duodenal ulcers, or accompanying acute erosive or haemorrhagic gastritis; pancreas, gallbladder, and intestinal fistula; prophylaxis and postoperative; and diabetic ketoacidosis. The company was founded in 2000 and is based in Haikou, the People’s Republic of China.

Founded in 2000

hainan shuangcheng pharmac-a (002693) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hainan shuangcheng pharmac-a (002693) Key Developments

Hainan Shuangcheng Pharmaceutical Co., Ltd. Approves Amendments to the Articles of Association

Hainan Shuangcheng Pharmaceutical Co., Ltd. at its Annual General Meeting held on February 27, 2015, approved Amendments to the articles of association of the company.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Approves 2014 Profit Distribution Plan, Payable on March 10, 2015

Hainan Shuangcheng Pharmaceutical Co., Ltd. announced that at the Annual General Meeting of 2014 held on 27 February 2015, the company approved 2014 profit distribution plan to distribute CNY 1.000000 per 10 shares. Record date on 09 March 2015, Ex-date on 10 March 2015 and Payment date on 10 March 2015.

Hainan Shuangcheng Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Mar 03, 2015

Hainan Shuangcheng Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Mar 03, 2015., at 14:30 China Standard Time. Agenda: To approve the eligibility for non-public share offering; to approve scheme for non-public share offering; to approve preplan (revised) for the non-public share offering; to approve feasibility report on use of proceeds from the non-public share offering (revised); Acquisition of 100% equity in a company and 46% equity in another company, and signing of conditional equity transfer agreement or framework agreement; to approve report on use of previously raised funds; to approve authorization to the board to handle matters in relation to non-public share offering; to approve the plan for the shareholders profit return for the next three years (2015-2017); to approve management measures for raised funds; and to approve acquisition of 46% equity in a company with surplus excessive raised funds from the IPO and funds to be raised from the non-public share offering; and to consider other issues.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002693:CH CNY13.63 CNY +0.02

002693 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002693.
View Industry Companies

Industry Analysis


Industry Average

Valuation 002693 Industry Range
Price/Earnings 92.8x
Price/Sales 32.7x
Price/Book 6.2x
Price/Cash Flow 93.5x
TEV/Sales 31.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAINAN SHUANGCHENG PHARMAC-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at